Search

Researchers at Capital Medical University in Beijing, China have investigated the potential therapeutic effects of the mitochondrial unfolded protein response (UPRmt) on ischemic stroke. They conducted experiments using in vivo and in vitro models of ischemic stroke and found that inducing UPRmt protected neurons against oxygen-glucose deprivation. They also discovered that meclizine, an FDA-approved drug, triggered UPRmt and provided neuroprotection. In a mouse model of cerebral ischemia, pretreatment with meclizine reduced infarction and improved neurological outcomes. These findings suggest that UPRmt could be a promising therapeutic target for ischemic stroke. [Extracted from the article]

A report from Mansoura University in Egypt discusses new research on antiemetic-antivertigo agents, specifically focusing on the drug Meclizine. The researchers developed two spectrofluorimetric methods for measuring Meclizine in raw materials and pharmaceutical dosage forms. These methods were found to be eco-friendly and environmentally benign. The research concludes that the proposed methods are effective for quantifying Meclizine and have potential applications in spiked human plasma. [Extracted from the article]

Researchers from Kalaburagi, India have published a new study on antiemetic-antivertigo agents. The study focused on designing mucoadhesive buccal tablets containing Meclizine Hydrochloride (MCZ HCL) to enhance bioavailability and reduce the frequency of dose administration. The researchers used HPMC and Carbopol in the tablet formulation and conducted optimization processes to determine the most effective formulations. The study found that the optimized formulation showed promising physiochemical characteristics, in-vitro drug release, mucoadhesive strength, and swelling index. Stability experiments also showed no significant changes in the amount of drug present. For more information, readers can refer to the German Journal of Pharmaceuticals and Biomaterials. [Extracted from the article]

A recent study conducted at the Jackson Laboratory in Bar Harbor, Maine, has found that the Nrf2 activator astaxanthin and the mTORC1 inhibitor meclizine can extend the lifespan of male mice by 12% and 8% respectively. However, these effects were not significant in females. The study also tested five other agents, including fisetin and dimethyl fumarate, but found no significant lifespan effects. The researchers suggest that these findings may provide insights into sex-specific aspects of aging. The study was supported by the NIH National Institute on Aging, the Glenn Foundation for Medical Research, and the US Department of Veterans Affairs. [Extracted from the article]

Cairo, Egypt, Africa, Life Science, Bacterial Polysaccharides, Bacterial Toxins, Benzhydryl Compounds, Biological Factors, Endotoxins, Enzymes and Coenzymes, Health and Medicine, Hydrocarbons, Kinase, Lipopolysaccharides, Meclizine, Neuroinflammation, Risk and Prevention Keywords: Cairo; Egypt; Africa; Life Science; Bacterial Polysaccharides; Bacterial Toxins; Benzhydryl Compounds; Biological Factors; Endotoxins; Enzymes and Coenzymes; Health and Medicine; Hydrocarbons; Kinase; Lipopolysaccharides; Meclizine; Neuroinflammation; Risk and Prevention EN Cairo Egypt Africa Life Science Bacterial Polysaccharides Bacterial Toxins Benzhydryl Compounds Biological Factors Endotoxins Enzymes and Coenzymes Health and Medicine Hydrocarbons Kinase Lipopolysaccharides Meclizine Neuroinflammation Risk and Prevention 4748 4748 1 11/06/23 20231110 NES 231110 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Life Science is now available. [Extracted from the article]

Keywords: Nagoya; Japan; Asia; Achondroplasia; Antiallergic; Anticholinergic Antiemetics; Antiemetic-Antivertigo Agents; Antiemetics; Antihistamines; Benzhydryl Compounds; Bone Diseases and Conditions; Central Nervous System Agents; Drugs and Therapies; Dwarfism; Genetic Diseases and Conditions; Health and Medicine; Hydrocarbons; Meclizine; Meclizine Therapy; Musculoskeletal Diseases and Conditions; Osteochondrodysplasias; Pediatrics; Pharmaceuticals EN Nagoya Japan Asia Achondroplasia Antiallergic Anticholinergic Antiemetics Antiemetic-Antivertigo Agents Antiemetics Antihistamines Benzhydryl Compounds Bone Diseases and Conditions Central Nervous System Agents Drugs and Therapies Dwarfism Genetic Diseases and Conditions Health and Medicine Hydrocarbons Meclizine Meclizine Therapy Musculoskeletal Diseases and Conditions Osteochondrodysplasias Pediatrics Pharmaceuticals 1215 1215 1 09/19/23 20230922 NES 230922 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Genetic Diseases and Conditions - AchondroplAsia is the subject of a report. The current study aimed to evaluate the safety and pharmacokinetics (PK) of meclizine in children with ACH after a 14-day-repeated dose of meclizine. [Extracted from the article]

Keywords: Antiallergic; Anticholinergic Antiemetics; Antiemetic-Antivertigo Agents; Antiemetics; Antihistamines; Benzhydryl Compounds; Central Nervous System Agents; Dosage Forms; Drugs and Therapies; Health and Medicine; Hydrocarbons; Meclizine; Meclizine Therapy; Pharmaceuticals; Pyridoxine; Therapy EN Antiallergic Anticholinergic Antiemetics Antiemetic-Antivertigo Agents Antiemetics Antihistamines Benzhydryl Compounds Central Nervous System Agents Dosage Forms Drugs and Therapies Health and Medicine Hydrocarbons Meclizine Meclizine Therapy Pharmaceuticals Pyridoxine Therapy 2860 2860 1 08/14/23 20230818 NES 230818 2023 AUG 18 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in antiemetic-antivertigo agents. Antiallergic, Anticholinergic Antiemetics, Antiemetic-Antivertigo Agents, Antiemetics, Antihistamines, Benzhydryl Compounds, Central Nervous System Agents, Dosage Forms, Drugs and Therapies, Health and Medicine, Hydrocarbons, Meclizine, Meclizine Therapy, Pharmaceuticals, Pyridoxine, Therapy. [Extracted from the article]